2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…2016 American Transplant Congress
Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.
Desensitization and incompatible live donor kidney transplantation (ILDKT) has improved survival vs. forgoing transplant or waiting for a compatible one. It is unknown if increased…2016 American Transplant Congress
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.
University of Cincinnati, Cincinnati.
Background. Desensitization results have largely focused on effects on anti-HLA antibody (HLA-Ab) and anti-ABO antibody levels. Anti-angiotensin II type 1 receptor antibody (AT1R-Ab) has recently…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HS pts (PRA>50%, DSA+ at transplant) who are transplanted without DES represent a significant risk for antibody-mediated rejection. Prior to transplantation, HS pts require…2016 American Transplant Congress
Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
INTRODUCTION: IVIG has become an essential tool in the treatment of sensitized patients prior to solid organ transplantation and is routinely used to treat viral…2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…2016 American Transplant Congress
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…2016 American Transplant Congress
The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplantation in HLA-sensitized patients. ADCC is one of the primary mechanisms for ABMR. IdeS cleaves…2016 American Transplant Congress
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
1Pathology, Emory University, Atlanta, GA; 2Emory Transplant Center, Emory University, Atlanta, GA.
AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 15
- Next Page »